Multi-Utilities

TIANJIN DEV released FY2025 Q1 earnings on August 28 (BJT), actual revenue HKD 859.29 M, actual EPS HKD 0.1605

TIANJIN DEV released FY2025 Semi-Annual Earnings on August 28 During-Market (BJT), actual revenue HKD 1.719 B, actual EPS HKD 0.321

TIANJIN DEV released FY2025 Q2 earnings on August 28 During-Market BJT, actual revenue HKD 859.29 M, actual EPS HKD 0.1605

TIANJIN DEV FY2025 Semi-Annual Earning Release on August 28, 2025 (BJT)

Tianjin Development Secures HK$100 Million Loan Financing

TIANJIN DEV released FY2024 9-month earnings on March 28 (BJT), actual revenue 2.59 B HKD, actual EPS 0.3896 HKD

TIANJIN DEV released FY2024 Q3 earnings on March 28 (BJT), actual revenue 769.58 M HKD, actual EPS 0.1211 HKD

TIANJIN DEV released FY2024 Q4 earnings on March 28 During-Market (BJT), actual revenue 769.58 M HKD, actual EPS 0.1211 HKD

TIANJIN DEV released FY2024 annual earnings during market hours on March 28 (BJT), actual revenue 3.359 B HKD, actual EPS 0.5108 HKD

TIANJIN DEV FY2024 Annual Earnings Release on March 28, 2025 During-Market BJT

Tianjin Development Signs HKD 100 Million Revolving Loan Financing Letter

Tianjin Development Releases Interim Results for 2024

Tianjin Development (00882) subsidiary Lisheng Pharmaceutical announced its performance for the three months ended March 31, 2024

Tianjin Development expects annual net profit to increase by about 70%-80%

Tianjin Development releases 2023 annual performance report of Lisheng Pharmaceutical

Tianjin Development signs a HKD 100 million revolving loan financing letter with a bank

Tianjin Development releases announcement, Lisheng Pharmaceutical expects net profit to increase by 263.2%-305.9% YoY in 2023

< 1B

1B - 5B

5B - 10B

10B - 50B

50B - 100B

100B - 500B

500B - 1T

≥ 1T

Market Value

Total Assets

< 100M

100M - 500M

500M - 1B

≥ 100B

Revenue

0 - 50M

50M - 100M

≥ 10B

Profits

< 0%

0% - 5%

5% - 10%

10 - 15%

15% - 20%

20 - 25%

25% - 30%

>= 30%

ROE(TTM)

= 0%

0% - 1%

1% - 3%

3% - 5%

5% - 8%

8% - 10%

>= 10%

Dividend Yield

0% - 10%

10% - 15%

20% - 30%

30% - 40%

40% - 50%

>= 50%

Net Profit Margin

0 - 0.05

0.05 - 0.1

0.1 - 0.2

0.2 - 0.4

0.4 - 0.6

0.6 - 0.8

0.8 - 1

>= 1

Asset Turnover

< 1.5

1.5 - 2

2 - 3

3 - 5

5 - 10

10 - 15

15 - 20

>= 20

Equity Multiplier

< 10%

10% - 30%

30% - 50%

50% - 70%

70 - 80%

80% - 90%

90% - 95%

>= 95%

Debt Ratio

WELIFE TECH

AV PROMOTIONS

MODERN LAND

CHINA AOYUAN

WT GROUP

LOGAN GROUP

C&N HOLDINGS

HANVEY GROUP

KFM KINGDOM

HOP FUNG GROUP

00882

Tianjin Development Holdings has announced the sale of its entire stake in Benefo Financial Leasing for RMB264.93 million to Tianjin Capital. This transaction, conducted through its subsidiary Tianjin Tai Kang, will result in Benefo ceasing to be a subsidiary of Tianjin Development following regulatory approvals. The sale reflects a strategic adjustment in Tianjin Development's portfolio in the financial leasing sector, adhering to Hong Kong Listing Rules for discloseable transactions.

Tip Ranks

TIANJIN DEV

Tianjin Development Sells Entire Stake in Benefo Financial Leasing for RMB265 Million

002393

Tianjin Development Holdings Limited announced that its affiliate, Tianjin Lisheng Pharmaceutical Co., Ltd., expects earnings growth for 2025, based on preliminary estimations. The company, in which Tianjin Development holds a 34.11% indirect stake, will provide final results in its 2025 Annual Report. This news is generated by Public Technologies and should not be considered financial advice.

Reuters

Lishengpharma

Lisheng Pharmaceutical, Tianjin Development Holdings Affiliate, Reports Indicative 2025 Earnings Growth

Tianjin Lisheng Pharmaceutical Co Ltd :SEES FY NET PROFIT ATTRIBUTABLE FOR TIANJIN LISHENG PHARMACEUTICAL RMB400 MILLION TO RMB440 MILLION

E Fund Hang Seng SCHK Innovative Drug ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Bosera Hang Seng SCHK Innovative Drug Select ETF

Minsheng Royal CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

Bosera Hang Seng Health Care ETF(QDII)

Yinhua CSI Innovative Drugs Industry ETF

Penghua CSI HK Connect Health Care Composite ETF

E Fund CSI 300 Health Care ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC SSE STAR Biology and Medicine ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Tianjin Development Posts FY Net Profit Attributable Guidance For Tianjin Lisheng Pharmaceutical

601166

TIANJIN DEV announced that last Wednesday (24th), its indirectly non-wholly-owned subsidiary Lishengpharma entered into the twelfth financial management agreement with INDUSTRIAL BANK, with a principal amount of RMB 85 million to subscribe for another structured deposit. The investment period is 182 days, with an expected annualized yield of 1.2% to 1.6%

AASTOCKS

INDUSTRIAL BANK

Tianjin Development's subsidiary invests RMB 85 million to subscribe to wealth management products

According to the Zhitong Finance APP, Tianjin Development announced that the company, as the borrower, has signed a financing agreement with a group of lenders (lenders) on September 17, 2025, for a term loan with a maximum limit of HKD 2 billion, with a term of 36 months from the date of drawdown

Zhitong

Tianjin Development has been granted a term loan with a ceiling of HKD 2 billion

According to the Zhitong Finance APP, Tianjin Development announced that on September 10, 2025, Lisheng Pharmaceutical (the company's indirectly non-wholly-owned subsidiary) entered into the 10th wealth management agreement with INDUSTRIAL BANK, with a principal amount of RMB 70 million (equivalent to approximately HKD 76.5864 million) to subscribe for another structured deposit

Tianjin Development's structured deposit with a subscription principal amount of 70 million yuan

According to the Zhitong Finance APP, TIANJIN DEV announced its interim results for the six months ending June 30, 2025, with revenue of HKD 1.719 billion, a year-on-year decrease of 5.59%; profit attributable to shareholders of HKD 344 million, a year-on-year increase of 19.57%; basic earnings per share of HKD 0.3211; and a proposed interim dividend of HKD 0.0518 per share

TIANJIN DEV released its interim results, with profit attributable to shareholders of HKD 344 million, an increase of 19.57% year-on-year

According to the Zhitong Finance APP, Tianjin Development announced that on June 19, 2025, Lifeng Pharmaceutical (an indirectly non-wholly-owned subsidiary of the company) entered into the ninth wealth management agreement with Xingyin Wealth Management and Industrial Bank, subscribing to another fixed-income investment product with a principal amount of RMB 50 million

Tianjin Development's subsidiary subscribes to a financial product worth 50 million yuan

According to the Zhitong Finance APP, TIANJIN DEV announced that the company, as the borrower, and a bank, as the lender, have signed a financing letter for a non-committed revolving loan of HKD 100 million on May 30, 2025. The term is one year from the acceptance of the financing letter

Tianjin Development has been granted a non-committed revolving loan financing of HKD 100 million

TIANJIN DEV announced its annual performance for the year ending December 31, 2024, with group revenue of HKD 3.359 billion, a year-on-year increase of 0.63%; profit attributable to shareholders was HKD 548 million, a year-on-year decrease of 13.78%; basic earnings per share were HKD 0.5109, and a final dividend of HKD 0.0882 per share is proposed. The company is primarily engaged in water supply and related services and operates power supply services within the Tianjin Development Zone

TIANJIN DEV released its annual performance, with a profit attributable to shareholders of HKD 548 million, a year-on-year decrease of 13.78%. It plans to declare a final dividend of HKD 0.0882 per share

According to the Zhitong Finance APP, Tianjin Development announced that Xia Binhui has been appointed as the company's executive director and deputy general manager, effective from December 30, 2024

Tianjin Development: Xia Binhui has been appointed as the executive director

Multi-Utilities(IN20308.HK)

Tianjin Development Sells Entire Stake in Benefo Financial Leasing for RMB265 Million

Lisheng Pharmaceutical, Tianjin Development Holdings Affiliate, Reports Indicative 2025 Earnings Growth

Tianjin Development Posts FY Net Profit Attributable Guidance For Tianjin Lisheng Pharmaceutical

Tianjin Development's subsidiary invests RMB 85 million to subscribe to wealth management products

Tianjin Development has been granted a term loan with a ceiling of HKD 2 billion